alexa
Reach Us +44-1235425476
The Prognostic Role of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value in Multiple or Oligometastatic Breast Cancer Patients | OMICS International
ISSN: 2155-9619
Journal of Nuclear Medicine & Radiation Therapy

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The Prognostic Role of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value in Multiple or Oligometastatic Breast Cancer Patients

Hala A El-Lathy1,4*, Ahlam A Dohal1, Yasser Alassiri2, Yasser Al Malki2 and Ehab Ibrahim3

1Department of Radiation Oncology, King Fahad Specialist Hospital, Dammam, Saudi Arabia

2Department of Nuclear Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia

3Departments of Medical Oncology, King Fahad Specialist Hospital, Dammam, Saudi Arabia

4Department of Clinical Oncology, Alexandria University, Egypt

Corresponding Author:
Hala A El-Lathy, MD
Department of Radiation Oncology
King Fahad Specialist Hospital, Dammam, Saudi Arabia
Tel: +966540367076
Fax: +96638412684
E-mail: [email protected]

Received Date: June 23, 2015; Accepted Date: July 22, 2015; Published Date: July 27, 2015

Citation: El-Lathy HA, Dohal AA, Alassiri Y, Malki YAl, Ibrahim E (2015) The Prognostic Role of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value in Multiple or Oligometastatic Breast Cancer Patients. J Nucl Med Radiat Ther 6:236. doi:10.4172/2155-9619.1000236

Copyright: © 2015 El-Lathy HA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nuclear Medicine & Radiation Therapy

Abstract

Purpose: To determine the prognostic role of pretreatment F-18FDG PET/CT maximum standardized uptake value (SUVmax) in metastatic breast cancer (MBC) patients and its correlation with clinicopathological parameters.
Materials and Methods: The pretreatment 18FDG-PET-CT SUVmax in MBC patients was compared with clinicopathological parameters. The prognostic value of pretreatment SUVmax for progression free survival (PFS) and overall survival (OS) were assessed using log rank test and cox regression analysis.
Results: Overall, 100 patients (77%) had evidence of visceral metastases while 30 patients (23%) had oligometastatic disease confined to bones only. The receiver operator curve (ROC) demonstrated that SUVmax of 4.4 and 7.7 to be the cutoff value for predicting PFS in patients with oligometastasis to bones and multiple metastatic disease respectively. Patients with bone oligometastasis SUVmax of >4.4 had a significantly shorter OS [Hazard ratio (HR 3.2)] <4.4 (P<0.0001),whereas patients with SUV max of ≤4.4 had significantly longer PFS compared with those with SUVmax >4.4 (P<0.001). Consequently, multiple metastatic patients with SUVmax ≤ 7.7 had significant improvement in OS compared to those with SUV max >7.7.On Cox regression analysis, the SUVmax category was the only factor correlated with both PFS (HR=4.5, 95% C I 3-6.8, P<0. 0001) and OS (HR=3.2, 95% C I 2.2-4.9, P<0. 0001) in patients with multiple metastasis.
Conclusions: The pretreatment 18FDG-PET-CT SUVmax showed a statistically significant association with different clinicopathological prognostic factors. In addition, it may be considered as a potential independent prognostic indicator of clinical outcomes in metastatic breast cancer.

Keywords

18FDG PET/CT SUVmax; Metastatic breast cancer

Introduction

Breast cancer represents a significant public health problem as it is the most common female cancer. It affects almost 1.4 million women worldwide and about 459,000 patients die due to this disease every year [1]. Approximately 6% of women with breast cancer have metastatic disease at the time of diagnosis and about 20% of patients initially diagnosed with localized disease will develop metastatic breast cancer (MBC) [2]. Despite significant improvements in the treatment of MBC during the last decade, it remains an incurable disease, with a median life expectancy of 18-30 months [3].

Hormone receptors (HR), estrogen receptor (ER) and progesterone receptor (PgR) and epidermal growth factor receptor (EGFR) play important roles in breast cancer development, progression and response to therapy. A clinically relevant subtype classification can be obtained by immunohistochemical (IHC) analysis of the tumor expression of ER, PgR, HER2 or Ki67. Five intrinsic subtypes have been identified luminal A (ER and PgR-positive, HER2-negative), luminal B (ER and/or PgR-positive, HER2-negative), luminal B like HER2- positive (ER and/or PgR-positive, HER2-positive),HER2 positive ER/ PgR negative and basal type ( triple negative) [4].

Microarray gene expression analysis (cDNA) has identified these intrinsic subtypes of breast cancer. However, cDNA analysis is not routinely performed to identify breast cancer as it is too complex and costly [5].Unfortunately, these available prognostic tools in MBC are of limited value because of the extensive heterogeneity in breast cancer biology and variable responses to treatment like endocrine therapy, chemotherapy, and novel targeted agents. Conventional imaging procedures are commonly used to detect distant metastases with or without second primary cancers in patients with cancers, with suboptimal sensitivities and specificities [6-9].Positron emission tomography/computed tomography (PET/CT) is a widely used diagnostic tool that combines anatomic with functional imaging using [18F]-2-fluoro-2-deoxy-D-glucose (FDG), a biomarker of cellular metabolism. It can detect enhanced glycolysis of cancer cells and has proven valuable in diagnosing, staging, detecting recurrences, and assessing response to therapy in a multitude of malignant disorders [10]. The standardized uptake value (SUV) of PET/CT is a semiquantitative simplified measurement of the tissue FDG accumulation rate, and studies of the head and neck, lung, esophageal, endometrial, cervical and renal cell cancer have explored the prognostic significance of the maximum standardized uptake value (SUVmax) [11-16]. Moreover, the improved diagnostic performance of PET/CT imaging over conventional imaging has been investigated in the staging of high-risk patients with early breast cancer and the detection of bone metastases in patients with metastatic breast cancer [17,18]. Recently, several studies reported the correlation between maxSUV of breast cancer and several clinicopathologic or immune-histochemical features [19-23].Limitations in published series include small numbers, lack of histologic correlates, and the intra individual variation in SUV by body site and motion artifact.

Therefore, in the current retrospective, single-institution study, we examined baseline FDG avidity on PET/CT images assessed by the maximum SUV (SUVmax), by body site, as a prognostic indicator of progression free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer presenting with multiple or oligometastatic disease (single/few detectable metastatic lesions) mainly to bones. Furthermore, identifying reliable prognostic markers would be of ultimate importance to individualize the management of patients with MBC (as surgical extirpation of the primary disease).

Material and Method

Retrospective review of breast cancer patients treated or referred to King Fahad Specialist Hospital-Dammam during the period between January 2010 and December 2012 after obtaining IRB approval. All patients signed informed consent. Electronic medical records were reviewed to determine known prognostic variables including: age, histology, grade, tumor phenotype (ER, PR, and HER2 expression), Ki 67 index and first-line treatment administered. Progression-free survival (PFS) was defined as the length of time from the date of the diagnosis to disease progression. Overall survival (OS) was defined as the interval between the date diagnosis and the date of death from any cause. We defined HR-positive, HER2-negative and Ki67 index <14% as luminal A, HRpositive and HER2-positive (or HER2-negative with Ki67 index ≥14%) as luminal B. Her-2/Neu status was defined positive when over-expressed with 3 plus staining in IHC or amplified with a ratio >2.2 by fluorescence in situ hybridization (FISH). Ki67 was visually scored for percentage of tumor cell nuclei with positive immunostaining above the background level by two pathologists.

Inclusion criteria

Female gender, 18 to70 years of age, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, life expectancy of >3 months, adequate bone marrow reserve, adequate liver and renal function, with no systemic or locoregional therapy in the metastatic setting. Biopsy proven invasive breast cancer by tru-cut biopsy, base line PET/CT as a part of staging work up, patients should have evidence of >1 FDG avid lesion at any of the following common metastatic breast cancer sites: bone, liver, lungs and non-regional lymph nodes.

Exclusion criteria

Patients who had excisional biopsy were excluded from the study because of higher incidence of inflammatory complications that may interfere with tumor imaging with PET/CT. In addition to patients who had received neoadjuvant chemotherapy or radiation therapy before undergoing PET/CT, brain metastasis at presentation, pregnancy or breast-feeding, history of diabetes mellitus, diagnosis of second primary malignancy, and active or uncontrolled infection.

Pretreatment 18F-FDG-PET-CT scan

The FDG-PET/CT scans were carried out using a Gemini XL PET/CT that combines a germanium oxyorthosilicate-based PET scanner and a 16-slice Brilliance CT scanner (Philips). All patients fasted for at least 6 hours before PET scans and had serum glucoselevels 7.8 mmol/L. Before and after injection, patients were kept lying comfortably in a quiet, dimly lit room. There was no significant difference in blood glucose levels measured at the time of the pre- and post-18 F-FDG studies. CT data were acquired first (120 kV, 100 mAs, no contrast enhancement). PET emission data were acquired in a 3-dimensional mode, with 3-5 min per bed position, and reconstructed using a 3-dimensional row-action maximum-likelihood algorithm.

The attenuation-corrected images were normalized for injected dose and body weight and converted into standardized uptake values (SUVs). The SUV was defined as (tracer concentration [kBq/mL])/ (injected activity [kBq]/patient body weight [g]). Image acquisition was started 1 h ± 10 min after intravenous administration of FDG (7.4 MBq/kg body weight). PET studies were acquired at 3-5 min per bed position, depending upon the patient’s weight and body habitus, for a total of six or seven bed positions. As per our protocol, low dose CT images were obtained with oral contrast only for attenuation correction. Interpretation of the dual PET-CT images was carried out by a nuclear medicine physician/radiologist trained in PET-CT. Lesions with standardized uptake value (SUV) of >2.5 were considered malignant. A region of interest was drawn at each pathologic site of tracer uptake, and the SUVs were calculated automatically by the computer using the body weight method: SUV_decay-corrected activity (kBq)/tissue (ml) injected FDG dose (kBq)/body weight (g). Maximum SUV was measured at every site of metastases, at the primary tumor (if present), and at each of the respective regional and distant nodal groups. For patients who had multiple metastatic sites, the single lesion with the highest SUVmax was used for calculation. Tumor size had to be a minimum of 1 cm to minimize partial volume averaging effects in FDG-PET interpretation. For visual analysis, abnormal FDG uptake was defined as substantially greater activity in the tissue than in the aortic blood on attenuation-corrected images. When abnormal FDG uptake was present in bone, the exact anatomic location of the abnormal uptake was identified on the CT images.

Statistical consideration

The impact of different clinical parameters on Baseline SUVmax was evaluated by Mann-Whitney U test (between 2 groups) or Kruskal- Wallis test (≥3 groups). Receiver operator characteristic (ROC) curves were used to identify potential SUV cutoffs values in patients with multiple and oligometastatic disease. An area under the curve of 1.0 would indicate a perfect test, whereas 0.5 would represent a noninformative test. Kaplan-Meier method was accessed for survival analysis. The SUVmax values are presented as medians and interquartile ranges (IQRs), because data were not normally distributed. Prognostic variables identified by univariate analysis, with P<0.1, were analyzed in the multivariate Cox model. All reported P-values were two-sided. Statistical significance levels were set at P<0.05. Disease free survival (DFS) and overall survival (OS) were calculated using the Kaplan Meier analysis. Log-rank test and Cox regression analysis were performed to correlate the various clinical and pathological parameters to treatment outcomes. All analyses were performed using SPSS 16.0 package program, (SPSS, Chicago, IL).

Results

The final analysis included 130 patients (median age, 50 years; range, 29-67years) who underwent PET/CT imaging a median of 14 days before MBC diagnosis (range, from 28 days before to 50 days after MBC diagnosis). Other baseline characteristics are provided in Table 1. The median time from diagnosis of MBC to disease progression was 19 months (range, 11.8-36.2 months). Most patients (n=109; 84%) initially had a clinically advanced stage breast cancer (stage III and IV) while the remaining 21 patients (16%) presented with stage II disease and all patients were subsequently found to harbor metastatic disease. The vast majority of patients (n=117; 90%) had invasive ductal carcinoma. With regards to tumor phenotype luminal A,B (ER/PR-positive) constituted the largest subgroup (n=64; 49%) whereas luminal B like, Her2neu positive and triple negative was encountered in 20%,16% and 15% of the studied patient population, respectively. Thirty one patients (24%) received endocrine therapy as their first-line treatment. Seventy-four patients (57%) received chemotherapy, and 25 patients (19%) received targeted therapy, possibly combined with chemotherapy or endocrine therapy. With regards to indications of PET /CT scanning as reported in patients files were: to further characterize nature of suspicious lesions detected on other radiologic studies in 65 patients (50%) and to assess patients presenting with either locally advanced breast cancer or with symptoms in (18%) and (25%) of patients respectively (Table 2). Overall, 100 patients (77%) had evidence of visceral with or without non regional lymph node metastases (defined as lung 38 patients (29%) or liver in 37 patients (28%) disease and nonregional lymph node metastasis 25 patients (19%) on PET/CT images). Moreover, bones as oligometastatic site, were observed in 30 patients (23%) of the studied population. In total, 110 patients (85%) had at least 1 biopsy result that confirmed the MBC diagnosis. Among the patients with FDG-avid lesions, according to anatomic site, the numbers with positive biopsies were as follows: bones, 25of 30 patients (83%); liver, 33 of 37patients (89%); LN, 23of 25 patients (92%); and lung, 29 of 38 patients (76%). The median SUVmax of the studied 130 patients was 13.3 ± 6.1 (range, 2.8-24.3). Median SUVmax was also significantly different among different tumor grade groups (P<0.001) and was increased by increases in the tumor grade. The SUVmax was significantly higher in triple negative tumors (P<0.001) and Her2neu positive tumors (P=0.03), compared to luminal A,B tumors respectively (Table 3).

Baseline Characteristic No. of Patients %
Age
≤50 57 43
>50 73 56
Tumor phenotype
Luminal A 30 23
Luminal B 34 26
Luminal B like 26 20
Her2 neu positive 21 16
Triple negative 19 15
Histology
Ductal 117 90
Lobular 9 7
Other 4 3
Grade
1 0  
2 18 14
3 112 86
Proliferation index
Ki 67% ≤ 14% 16 12
Ki 67% ≥ 14% 114 87
Stage at initial breast cancer diagnosis
Stage I 0  
Stage II 21 16
Stage III 46 35
Sage IV 63 49
Indications for PET/CT
Other abnormal radiology 65 50
Locally advanced breast cancer 23 18
Symptoms 32 25
Indication not determined 10 7
First therapy for MBC
Endocrine therapy 31 24
Targeted with or without endocrine therapy 25 19
Chemotherapy 74 57

Table 1: Baseline characteristics of the studied group of patients.

Disease Site SUV max Values
Bone N=30
Median 4
Range 5.2 (2.8-8)
Low quartile 3
High quartile 5
Liver N=37
Median 13.4
Range 17.8(5.2-23)
Lowquartile 8.9
Highquartile 19.1
Lung N=38
Median 8.9
Range 12.7 (5.3-18)
Low quartile 6.7
High quartile 17.4
Lymph node N=25
Median 10
Range 13.4 (5.1-18.5)
Low quartile 7
High quartile 17

Table 2: Maximum standardized uptake value by disease site.

Baseline Characteristic No. of Patients % Baseline SUVmax
Median P value
Age
≤50 57 43 6.3 0.456
>50 73 56 6.9  
Tumor phenotype
Luminal A 30 23 5.7 0.234
Luminal B 34 26 6.8 0.544
Luminal B like 26 20 7.9 0.136
Her2 neu positive 21 16 9.2 0.03*
Triple negative 19 15 11.8 <0.001*
Histology
Ductal 117 90 6.5  
Lobular 9 7 5.8 0.453
Other 4 3 7.8  
Grade
1 0      
2 18 14 7  
3 112 86 9.8 <0.001*
Proliferation index
Ki 67% ≤14% 16 12 4.8  
Ki 67% ≥14% 114 87 9.8 <0.001*
Metastatic sites
Visceral 100 77 10  
Bone only 30 23 4 0.005*
No. of metastatic sites
1 49 38 4  
2 30 23 6.8 0.003*
≥3 51 39 9.8  
First therapy for MBC
Endocrine therapy 31 24 4  
Targeted ± endocrinetherapy  25  19  6.6 0.643
Chemotherapy  74  57  8.7  

Table 3: Baseline SUVmax comparison between and among groups.

In patient presented with breast cancer metastasizing to bone only, the receiver operator curve (ROC) demonstrated a SUVmax of 4.4 to be the optimal cutoff for predicting PFS (area under the curve: 0.681; standard error: 0.0678). A SUVmax of 4.4 yielded a sensitivity of 68.7% and a specificity of 78.5% for predicting the PFS (Figure 1). Similarly, patient presented with multiple metastatic disease, the receiver operator curve (ROC) demonstrated a SUVmax of 7.7 to be the optimal cutoff for predicting PFS (area under the curve: 0.837; standard error: 0.058). A SUVmax of 7.7 yielded a sensitivity of 88% and a specificity of 82.5% for predicting the PFS (Figure 2).

nuclear-medicine-operator-curve

Figure 1: The receiver operator curve (ROC) in breast cancer metastasizing to bone only.

nuclear-medicine-receiver-operator

Figure 2: The receiver operator curve (ROC) in multiple metastatic breast cancer patients.

Standard prognostic variables

We first examined known prognostic variables (intrinsic phenotype, metastatic disease site, first line treatment, age, tumor grade and histology) for the whole cohort irrespective of disease site and demonstrated the inferior OS of patients with triple-negative disease (negative for ER, PR, and HER2; HR, 2.8) compared with luminal A,B( ER/PR-positive and HER2-negative disease) (P<0.01) (Figure 3). Similarly, patients who had visceral metastases (N=75) had inferior survival (HR, 1.6; P=0.04) compared with patients who did not. Patients who received targeted therapy (including with endocrine therapy or chemotherapy) or chemotherapy alone in the first-line setting had significantly decreased survival (P=0.002; HR, 1.8 and 3.6, respectively) compared with patients who received endocrine therapy. It is noteworthy that grade (P=0.08), age (P=0.35), and histologic subtype (P=0.75) had no significant effect on prognosis.

nuclear-medicine-Overall-survival

Figure 3: Overall survival of different phenotypes.

Maximum standard uptake value as a prognostic variable

A strong correlation between the SUVmax cut off value 4.4 in bone and OS was observed in the survival analysis using the Kaplan- Meier method. As patients with a SUVmax of more than 4.4 had a significantly shorter OS (HR, 3.2) than patients with less than 4.4 (P<0.0001) (Figure 4). The magnitude of this effect was smaller than the effect of other variables, such as triple- negative histology (HR, 4.16; P<0.001). Furthermore, patients with bone metastasis having SUV max of 4.4 or less median progression free was not reached, consequently they had significantly longer progression free survival compared to patients with more than 4.4 in their bone metastasis (P<0.001) (Figure 5). Additionally, it was observed that patient presenting with multiple metastasis with SUV max cut off ≤7.7 had significant improvement in OS (HR, 2.2) and PFS (HR, 2.5) compared to those patients with SUV max cut off value >7.7 (Figure 6). On multivariate analysis, the SUVmax category was the only factor associated with PFS (HR)=8.4, 95% CI 1.2-54.8, P<0.026) but not OS (P=0.99) in oligometastatic patients to bones only. Additionally, the SUVmax category was the only factor correlated with both PFS (Hazard ratio (HR)=4.5, 95% C I 3-6.8, P<0. 0001) and OS (HR=3.2, 95% C I 2.2-4.9, P<0. 0001) in multiple metastatic patients.

nuclear-medicine-bone-metastasis

Figure 4: Overall survival for patients with bone metastasis.

nuclear-medicine-free-survival

Figure 5: Progression free survival for patients with bone metastasis.

nuclear-medicine-multiple-visceral

Figure 6: Progression free survival for patients with multiple visceral metastases.

Discussion

Various pathological prognostic indicators such as intrinsic phenotypes, metastatic disease sites, first line treatment, age, tumor grade and histology have been proposed for the risk stratification of MBC patients but they can only be obtained after surgery. On the other hand, F-18FDG PET can provide quantitative information about tumor glucose metabolism, which represents the aggressiveness of the malignant lesion. FDG uptake can be evaluated noninvasively and be measured with good inter-test reproducibility [24].

In the present study, 100 patients (77%) had evidence of visceral metastases with or without non regional lymph node involvement. While oligometastatsis to bones only, were observed in 30 patients (23%). In total, 110 patients (85%) had at least 1 biopsy result that confirmed the metastatic breast cancer diagnosis. The SUVmax was significantly higher in triple negative tumors (P<0.001) and Her2 neu positive tumors (P=0.03) compared to luminal A and B tumors respectively. Kim et al. also reported that triple negative tumors had a significantly higher maxSUV than non-triple negative tumors (p=0.016) [25]. Similarly, Basu et al. observed that triple negative breast tumors were associated with enhanced FDG uptake commensurate with their aggressive biology [19].

On univariate analysis, there was inferior OS for patients with triple-negative disease (HR 2.8) compared with luminal A and B (ER/ PR-positive and HER2-negative disease) (P<0.01). Moreover, patients who had visceral metastases (N=100) had inferior survival (HR, 1.6; P=0.04) compared to patients who did not. Zhang et al. also reported that the presence of visceral metastasis (P=0.035), number of metastatic sites (P=0.002), chemotherapy as the first-line therapy after PET/CT (P=0.037) were significantly associated with shorter PFS and OS [26]. It is noteworthy that: grade (P=0.08), age (P=0.35), histologic subtype (P=0.75) had no significant effect on prognosis. Morris et al reported comparable results, as grade (P=0.09), age (P=0.45), histologic subtype (P=0.95) were found to have no significant impact on survival [27].

To the best of our knowledge, this retrospective study represents the first series that succeeded to find out different cut off values of baseline 18 F PET-CT FDG SUVmax uptake for breast cancer patients presenting with multiple visceral or oligometastasis to bones (7.7 and 4.4) respectively. In the current study, patients presenting with multiple metastases with SUV max cut off ≤7.7 had significant improvement in OS (HR, 2.2) and PFS (HR, 2.5) compared to those patients with SUV max cut off value >7.7. On multivariate analysis, the SUVmax category was the only factor correlated with both PFS (Hazard ratio (HR)=4.5, 95% C I 3-6.8, P<0. 0001) and OS (HR=3.2, 95% C I 2.2-4.9, P<0.0001). Furthermore, these SUVmax cut off values yielded a sensitivity of 88% and a specificity of 82.5% for prediction the PFS in patients presenting with multiple visceral metastases. This finding was also confirmed previously in other trials [28,29]. Bong et al. reported a cut off value of 6.6 for the SUVmax for the whole group without segregation of patients according to the site of metastasis (visceral or bone) and he also demonstrated longer survival in patients with a lower SUV [28].

Additionally, patients with bone metastasis having SUVmax of >4.4 had a significantly shorter OS (HR 3.2) than patients with <4.4 (P<0.0001). Moreover, the SUVmax cutoff value of 4.4 in oligometastasis to bones achieved sensitivity and specificity in predicting PFS of 68.7% and 78.5% respectively. Correspondingly, Morris et al observed a strong correlation between the SUVmax in bone and OS (P<0.001). By using the tertile with the lowest SUVmax as the reference group (median, 4.7; range, 2.1-5.8), patients in the highest tertile of SUVmax (median, 11.2, range, 9.3-29.6) had the shortest survival (HR, 3.13) [27].

The current study has several strengths

First: it included a broad representation of various intrinsic subgroups of breast cancer.

Second: 110 patients (85%) had at least 1 biopsy result that confirmed the MBC diagnosis (the gold standard), which contrasts to some other series in which the diagnostic performance of PET/CT imaging was compared with other imaging modalities.

Third: we correlated FDG uptake (SUVmax) with OS, which is a clean endpoint, as this considers both variable tumor biology and treatment administered.

There are limitations to the current study: it was retrospective, it did not assess tumor: background ratios, it included a heterogeneous population both in terms of variable follow up imaging (timing and modality) and treatment regimens administered. Although 85% of patients underwent a biopsy of at least 1 site, we cannot be absolutely sure that all of the FDG-avid lesions observed on PET/CT images truly represented MBC. Furthermore, we examined PET/CT imaging from only 1 time-point and thus are unable to comment on the prognostic effect of PET/CT imaging (with regard to treatment effect). Finally, because this was a retrospective study, the cost-effectiveness of PET/ CT imaging could not be assessed.

Conclusion

This study demonstrates that the pretreatment 18FDG-PET-CT SUVmax showed a statistically significant association with different clinicopathological prognostic factors. In addition, it may be considered as a potential independent prognostic indicator of clinical outcomes in metastatic breast cancer patients.Ultimately prospective studies will be needed to further validate the prognostic potential of pretreatment 18FDG-PET-CT SUVmax in MBC patients.

Conflict of Interest

All authors confirm that there is no conflict of interest and they all agree to the manuscript. No financial support nor grants were offered to this research.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 12977
  • [From(publication date):
    July-2015 - Jul 18, 2019]
  • Breakdown by view type
  • HTML page views : 9147
  • PDF downloads : 3830
Leave Your Message 24x7
Top